Recent investigations have unveiled that small-molecule tyrosine kinase inhibitors, PKC412 and LOXO-101, exhibit promise in CFS treatment by suppressing TRK activation (Chi et al., 2012; Nagasubramanian et al., 2016) (Figures 5C, D). Here, NTRK1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.